Jan A van Noord

Summary

Affiliation: Atrium Medical Centre
Country: The Netherlands

Publications

  1. pmc Prediction and course of symptoms and lung function around an exacerbation in chronic obstructive pulmonary disease
    Maarten van den Berge
    Department of Respiratory Medicine, University Medical Center Groningen, GRIAC Research Institute, University of Groningen, Groningen, The Netherlands
    Respir Res 13:44. 2012
  2. ncbi request reprint Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD
    J A Van Noord
    Dept of Respiratory Diseases, Atrium Medisch Centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
    Eur Respir J 26:214-22. 2005
  3. ncbi request reprint Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD
    Jan A van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
    Chest 129:509-17. 2006
  4. doi request reprint The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients
    J A Van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Heerlen, The Netherlands
    Respir Med 103:22-9. 2009
  5. doi request reprint Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms
    J A Van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
    Respir Med 104:995-1004. 2010
  6. doi request reprint QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease
    Jan A van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Heerlen, The Netherlands
    Thorax 65:1086-91. 2010
  7. doi request reprint 24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD
    J A Van Noord
    Dept of Respiratory Diseases, Atrium Medisch Centrum, The Netherlands
    Pulm Pharmacol Ther 24:666-72. 2011
  8. pmc Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial
    Anthony D'Urzo
    Department of Family and Community Medicine DFCM, University of Toronto, Ontario, Canada
    Respir Res 12:156. 2011

Collaborators

  • Tim Overend
  • Roland Buhl
  • B Disse
  • Craig LaForce
  • Maarten van den Berge
  • Anthony D'Urzo
  • Emiel F M Wouters
  • Thys van der Molen
  • Dirkje S Postma
  • Ad J M Schreurs
  • Wim C J Hop
  • Jacques P H M Creemers
  • Donald Banerji
  • Kazuto Hirata
  • Carmen Martin
  • Yimeng Lu
  • Gary T Ferguson
  • Rachael Horton

Detail Information

Publications8

  1. pmc Prediction and course of symptoms and lung function around an exacerbation in chronic obstructive pulmonary disease
    Maarten van den Berge
    Department of Respiratory Medicine, University Medical Center Groningen, GRIAC Research Institute, University of Groningen, Groningen, The Netherlands
    Respir Res 13:44. 2012
    ..We investigated the course of exacerbations in the published COSMIC study that investigated the effects of 1-year withdrawal of fluticasone after a 3-month run-in treatment period with salmeterol/fluticasone in patients with COPD...
  2. ncbi request reprint Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD
    J A Van Noord
    Dept of Respiratory Diseases, Atrium Medisch Centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
    Eur Respir J 26:214-22. 2005
    ..i.d. A combination of both drugs q.d. was most effective and provided an additive effect throughout the 24-h dosing interval...
  3. ncbi request reprint Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD
    Jan A van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
    Chest 129:509-17. 2006
    ..The combination of short-acting beta(2)-agonists and anticholinergics in the treatment of COPD has been well documented, but data on combination of long-acting agents are lacking...
  4. doi request reprint The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients
    J A Van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Heerlen, The Netherlands
    Respir Med 103:22-9. 2009
    ..The Respimat Soft Mist Inhaler (SMI), a novel, propellant-free inhaler, has been developed and proposed as an alternative delivery device for use with tiotropium...
  5. doi request reprint Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms
    J A Van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
    Respir Med 104:995-1004. 2010
    ..Clinical information on 24-h spirometric efficacy of combining tiotropium and salmeterol compared to single-agent therapy is lacking in patients with COPD...
  6. doi request reprint QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease
    Jan A van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Heerlen, The Netherlands
    Thorax 65:1086-91. 2010
    ....
  7. doi request reprint 24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD
    J A Van Noord
    Dept of Respiratory Diseases, Atrium Medisch Centrum, The Netherlands
    Pulm Pharmacol Ther 24:666-72. 2011
    ..Olodaterol is a novel long-acting β(2)-adrenoceptor agonist with a pre-clinical profile that suggests 24-h bronchodilation may be achieved with once-daily administration...
  8. pmc Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial
    Anthony D'Urzo
    Department of Family and Community Medicine DFCM, University of Toronto, Ontario, Canada
    Respir Res 12:156. 2011
    ..The glycopyrronium bromide in COPD airways clinical study 1 (GLOW1) evaluated the efficacy, safety and tolerability of NVA237 in patients with moderate-to-severe COPD...